Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Pyoderma Gangrenosum: Overview, Diagnosis, and Treatment Strategies
Description
The discussion centered on pyoderma gangrenosum (PG), an inflammatory skin condition characterized by painful, rapidly expanding ulcers. A case study was presented involving a patient with significant comorbidities, including diabetes and ulcerative colitis, who exhibited a non-healing ulcer despite various treatments. Expert panelists emphasized the importance of accurate diagnosis through histology, noting that PG often requires a biopsy to exclude other conditions. The panel addressed different diagnostic criteria developed over the years, underlining their reliance on clinical judgment in practical settings. Treatment strategies for PG include systemic therapies like steroids and cyclosporine, which help suppress inflammation, along with optimizing wound care for healing. The panel discussed the equivalence of these treatments and the necessity for long-term immunosuppressive therapy post-initial treatment. They acknowledged the growing relevance of new therapies targeting inflammatory pathways in PG. Experts highlighted the need for careful monitoring and evaluation of treatment response within specific time frames. Ultimately, the panel provided treatment insights tailored to unique patient situations, moving towards a more integrated and individualized approach in managing this challenging condition.
View moreConclusions
- Pyoderma Gangrenosum (PG) is a rare inflammatory disorder characterized by an imbalance in the innate and adaptive immune systems.
- The typical presentation of PG includes rapidly expanding, painful ulcers with specific characteristics such as violaceous borders.
- Biopsy is essential for diagnosis and should be performed from the ulcer edge to rule out other conditions, despite the risk of pathergy.
- Recent diagnostic criteria aim to improve the identification of PG, differentiating it from other ulcerative conditions.
- There is currently no FDA-approved treatment for PG, and management typically involves immunosuppressive therapies.
- Systemic corticosteroids and cyclosporine are commonly used to suppress inflammation, but other agents may be necessary for long-term management.
- New therapies are being explored, including IL-17 inhibitors, IL-23 inhibitors, and JAK inhibitors, which show promise in clinical trials.
- Successful management of PG often requires a combination of therapies tailored to each patient's individual response and underlying conditions.
- Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum. Nat Rev Dis Primers 2020;6(1):81.
- Su WP, Davis MD, Weening RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43(11):790-800.
- Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. Br J Dermatol. 2019;180(3):615. Epub 2018 May 6.
- Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, Marzano AV, Wallach D, Kim K, Schadt C, Ormerod A, Fung MA, Steel A, Patel F, Qin R, Craig F, Williams HC, Powell F, Merleev A, Cheng MY. JAMA Dermatol. 2018;154(4):461.
- Kamal K, Xia E, Li SJ, et al. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group. J Invest Dermatol 2024;144(6):1295-1300.e6.